Q2 Earnings Estimate for Pharvaris Issued By HC Wainwright

Pharvaris N.V. (NASDAQ:PHVS) – Equities researchers at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for shares of Pharvaris in a report released on Thursday, May 14th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.69) for the quarter, up from their prior forecast of ($0.89). HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($3.35) per share. HC Wainwright also issued estimates for Pharvaris’ Q3 2026 earnings at ($0.76) EPS, Q4 2026 earnings at ($0.83) EPS, FY2026 earnings at ($2.98) EPS, FY2027 earnings at ($2.41) EPS, FY2028 earnings at ($0.02) EPS, FY2029 earnings at $3.23 EPS and FY2030 earnings at $6.59 EPS.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12.

A number of other research firms have also weighed in on PHVS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Royal Bank Of Canada reduced their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Wolfe Research began coverage on Pharvaris in a research note on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective for the company. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Finally, Wedbush lifted their price objective on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.

Pharvaris Stock Performance

NASDAQ PHVS opened at $28.81 on Tuesday. The stock has a 50-day simple moving average of $28.20 and a two-hundred day simple moving average of $26.63. The firm has a market capitalization of $1.88 billion, a P/E ratio of -9.06 and a beta of -2.34. Pharvaris has a fifty-two week low of $15.46 and a fifty-two week high of $33.33.

Insider Activity

In other news, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the firm’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $30.32, for a total transaction of $881,402.40. Following the sale, the director directly owned 355,167 shares in the company, valued at $10,768,663.44. This trade represents a 7.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anne Lesage sold 19,200 shares of the firm’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $30.26, for a total value of $580,992.00. Following the sale, the insider owned 133,969 shares in the company, valued at $4,053,901.94. This trade represents a 12.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 150,659 shares of company stock worth $4,489,587 in the last ninety days.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently modified their holdings of the business. California State Teachers Retirement System grew its position in shares of Pharvaris by 2.2% during the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after acquiring an additional 520 shares during the period. JPMorgan Chase & Co. grew its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Pharvaris in the 4th quarter worth about $35,000. Public Employees Retirement System of Ohio boosted its holdings in Pharvaris by 20.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after buying an additional 1,300 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after buying an additional 1,695 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.